iRadimed

IRMD

Market cap $1.27B

Nine Ten Capital Management sold 342,907 shares of IRadimed; the estimated transaction value was $29.42 million based on quarterly average price. The quarter-end position value decreased by $13.21 million, reflecting both share sales and price changes.

For the 18th time in a row, the niche medical device maker set a new all-time high for quarterly revenue. It also handily topped the consensus analyst estimate for adjusted net profit.

IRADIMED CORPORATION (IRMD) Q4 2025 Earnings Call Transcript

ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the quarter and year ended December 31, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) non-magnetic patient vital signs monitoring systems that are each designed for use during MRI procedures.

ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per share of the Company's outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 17, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company produces the only known non-magnetic intravenous (“IV”) infusion pump system and a non-magnetic patient vital signs monitoring system designed for use during MRI procedures.

Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance

Iradimed's CEO, President, and Chairman of the Board, Roger Susi, recently sold 5,000 shares on the open market. The transaction represented roughly 1% of his indirect holdings.

IRADIMED CORPORATION ( IRMD ) Q3 2025 Earnings Call November 3, 2025 11:00 AM EST Company Participants Roger Susi - Founder, Chairman, CEO & President John Glenn - CFO & Corporate Secretary Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Kyle Bauser - ROTH Capital Partners, LLC, Research Division Presentation Operator Welcome to the IRADIMED CORPORATION Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded today, November 3, 2025, and contains time-sensitive accurate information that is valid only for today.

Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance

ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 third quarter financial results before the market opens on Monday, November 3, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.